Business
Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference
ATLANTA--(BUSINESS WIRE)-- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination
About this update from Dogwood Therapeutics, Inc.
[{"type":"text","content":" ATLANTA--(BUSINESS WIRE)--\nVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Q3 Virtual Investor Summit. During the presentation, the Company will provide an overview of its business and corporate strategy as well as upcoming key catalysts. The presentation will be webcast and an archived recording will be made available in Investors' section of the Virios website.\n\n\n\nEvent:\n\n\n\n\nQ3 Investor Summit\n\n\n\n\n\nDate:\n\n\n\n\nAugust 16 & 17th, 2022\n\n\n\n\n\nPresentation:\n\n\n\n\nAugust 17th @ 10:15 a.m. ET\n\n\n\n\n\nLocation:\n\n\n\nhttps://us06web.zoom.us/webinar/register/WN_kxGOK9_8SPeCtG6FMrV3mQ\n\n\n\n1x1s will be available for qualified investors\n\n\nThe conference is completely complementary to qualified investors. Please register at Complimentary Investor Registration.\n\n\nFor more information, please visit www.virios.com.\n\nAbout Virios Therapeutics\n\nVirios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (“FM”). Immune responses related to the activation of tissue resident herpes have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease, chronic fatigue syndrome and other functional somatic syndromes, all of which are characterized by waxing and waning symptoms with no obvious etiology. Our lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 has been granted fast track designation by the FDA and is currently being tested in a multi-center, randomized, double-blind, placebo-controlled trial (“FORTRESS”), designed to potentially serve as a supportive registrational study. Evidence of IMC-1’s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.\n\nThe Company is pursuing a second development...